Dr. Vodicka, a Head of the Department of Molecular Biology of Cancer, Institute of Experimental Medicine in Prague, has published more than 175 (total IF 750, over 4000 citations a HI 37) scientific articles in peer-reviewed journals (see PubMed). He acted as principal investigator on numerous national and international grants. Dr. Vodicka was a member of international scientific committee for several international conferences and acts in the editorial board of international peer-reviewed journals. He In 2004 and 2005 he acted as an expert for evaluating carcinogenic risks of chemicals within the programmed of US State Department of Health and NIES, Research Triangle Park, NC, USA. He is involved in the evaluation of reports within 6th and 7th EU FP, in evaluation of grant applications within ESC and Horizon2020, EU Commission, Brussels, Belgium, and collaborates with UICC, Geneve, Switzerland. Dr. Vodicka has been working (2002-2008, 2012-2016) for the National Science Foundation of the Czech Republic and was reviewing submissions to numerous international journals (e.g. Carcinogenesis, Int. J. Cancer, Mutat. Res., Chem. Res. Toxicol., Clin. Cancer Research, Gut and others). He has received (2009) an award at 14th World Congress on Advances in Oncology, Loutraki, Greece. Since 2004 the main topics of research were focused on the DNA repair functional tests in relation to the markers of DNA and chromosomal damage. Tests are performed on human material, collected in the frame of several projects (molecular epidemiology approach). Furthermore, numerous susceptibility genes have been investigated regarding sporadic colorectal cancer in humans. PV has participated on the multicentric genome-wide association study aimed at the identification of susceptibility loci in colorectal cancer patients. Recently, Dr. Vodicka was appointed as Guest Editor for preparing Special Issue of the journal Mutagenesis (IF 3.983; http://mutage.oxfordjournals.org/content/27/2.toc), entitled Colorectal Cancer-Current Insights into Susceptibility.
Pavel Vodicka(Research Area)
- Studies on specific DNA and chromosomal damage, related to the environmental and occupational exposure exposure in healthy subjects in relation to the disease onset (cancer)
- Functional tests on DNA repair (repair capacity, phenotype) in healthy subjects and their involvement in carcinogenesis
-Molecular mechanisms of carcinogenesis - genetic and epigenetic factors involved
-Predisposition to gastrointestinal cancers (colorectum, pancreas), genetic susceptibility
-The effectivity of chemotherapy in cancer patients (susceptibility, resistance, adverse effects, toxicity)
Prof. Yoko Matsumoto is a Professor of Department of Life Sciences at Sojo University, Japan. She received her PhD in Pharmacy from Kyushu University, Japan. She was a visiting researcher in Colorado University at Boulder with Prof. Tom Cech. Yoko Matsumoto has received Outstanding Female Researcher Award from the Society of Chemical Engineering, Japan. She is a member of the Board for Japan Nanomedicine Society and Councilor for Japanese Association for Molecular Target Therapy of Cancer. Her current research interest focuses on liposomes for therapeutic applications. She has published more than 130 original paper
Yoko Matsumoto (Research Area)
Her current research interest focuses on liposomes for therapeutic applications
Dr. Xianming Mo is a professor of internal medicine and acts as Director of Laboratory of Stem Cell Biology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University. He obtained his medicine degree from North Sichuan Medical College. Then he was trained in pathology and accept Master of Medicine in West China University of Medical Science. After obtaining a PhD degree in Peking Union Medical College, He moved to Humboldt-UniversitÃ¤t zu Berlin and then to Medical College of Georgia as postdoctoral fellows. Then, he became junior faculty in Medical College of Georgia and senior scientist in Max Delbruck Center for Molecular Medicine. In 2006, he returned back to West China Hospital.
Dr. Xianming Mo (Research Area)
Xianming Mo is interested in understanding the biology of physiological and pathological tissue stem cells including hematopoietic stem cell, neural stem cell and epithelial stem cells. Now one of his works focuses on the biology of the cancer stem cells, the constitution of cancer tissues in human patients with carcinoma and their therapeutic implications in cancer.
Professor & Chair of Cancer Immunology
Plymouth University Peninsula School of Medicine
PhD, Molecular Medicine, London School of Tropical Medicine & Hygiene, University of London, UK
MMed, Medicine, Sun Yat-Sen University College of Medicine, Guangzhou, China
MD, Medicine, Suzhou Medical College, Suzhou, China
2007â€“2015: Deputy Lab Head/Tenured Scientist, Weatherall Institute of Molecular Medicine, University of Oxford, UK;
2002â€“2007: Tenured Staff Scientist/Deputy Lab Head, Cancer Research UK (CRUK), UK;
1999â€“2002: Research Fellow, Imperial Cancer Research Fund (ICRF), UK;
1996â€“1999: Postdoc Research Associate, Department of Biochemistry, University of Oxford, UK.
Ji-Liang Li(Research Area)
My research interest focuses on tumour microenvironment and translational cancer medicine. By employing a variety of approaches including molecular biology, cell biology, immunology, proteomics, next-generation sequencing, bioinformatics, animal models, human tumour samples and relevant clinical data, my research is dedicated to delineate mechanisms on how key molecules (such as microRNAs, lncRNAs, and RN181 E3 ligase), signalling pathways (such as Notch signalling), tumour cells, and tumour stromal cells (such as endothelial cells, infiltrating lymphocytes, tumour-associated macrophages, and tumour-associated fibroblasts) in tumour microenvironment regulate tumour growth and metastasis and tumour response to therapeutic interventions (in particular, cross-interactions among radiotherapy, chemotherapy, targeted therapy and immunotherapy). My aims are (1) to dissect mechanisms of tumour migration, invasion and metastasis, (2) to develop novel therapeutic targets or biomarkers, and (3) to improve therapeutic efficacy by optimal combinations of radiotherapy, chemotherapy, targeted therapy, or immunotherapy. Primary cancer types I am currently working on include, but not limit to, brain tumour (eg, gliomas), gastrointestinal tumour (eg, gastric, colorectal and hepatic cancer), and head & neck cancer (eg, nasopharyngeal carcinoma).
Spiegel is currently on the Board of Directors of the International Alliance of Patient Organizations (IAPO) and serves as the Chair of the Fundraising Committee. He has also served on the Stand Up to Cancer Advocate Advisory Council. He is a co-founder and currently serves on the steering committee of the Alliance for Safe Biologic Medicines (ASBM). He is on the Board of Directors, and in December 2014 was elected to Chair, of the Digestive Disease National Coalition (DDNC), a founding member of the Coalition to Increase Clinical Trial Participation as well as an active member of many other health care coalitions and organizations.
Andrew Spiegel(Research Area)
Biosimilar policy development, IP protections for medicines, health technology assessments, personalized medicine